# Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular

> **NCT04141241** · PHASE2 · COMPLETED · sponsor: **Bota Bio Co., Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus With Circulatory Complciation

## Interventions

- **DRUG:** Ecklonia cava Phlorotannin

## Key facts

- **NCT ID:** NCT04141241
- **Lead sponsor:** Bota Bio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-04
- **Primary completion:** 2018-05-04
- **Final completion:** 2018-05-04
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141241, "Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04141241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*